Kelly M Loyet

List of Publications by Year
in descending order

18	1,216	759233 12	940533 16
papers	citations	h-index	g-index

18	18	18	2231
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Novel antibodyâ€“antibiotic conjugate eliminates intracellular S. aureus. Nature, 2015, 527, 323-328.	27.8	663
2	Mass Spectrometric Contributions to the Practice of Phosphorylation Site Mapping through 2003. Molecular and Cellular Proteomics, 2005, 4, 235-245.	3.8	99
3	An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma. Cell, 2019, 179, 417-431.e19.	28.9	76
4	Activation of the Alternative Complement Pathway in Vitreous is Controlled by Genetics in Age-Related Macular Degeneration. , 2012, 53, 6628.		68
5	Structural and Functional Analysis of a C3b-specific Antibody That Selectively Inhibits the Alternative Pathway of Complement. Journal of Biological Chemistry, 2009, 284, 10473-10479.	3.4	53
6	Proteomic Profiling of Surface Proteins on Th1 and Th2 Cells. Journal of Proteome Research, 2005, 4, 400-409.	3.7	49
7	Complement Inhibition in Cynomolgus Monkeys by Antiâ€“Factor D Antigen-Binding Fragment for the Treatment of an Advanced Form of Dry Age-Related Macular Degeneration. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 527-537.	2.5	41
8	Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules. Translational Vision Science and Technology, 2019, 8, 1.	2.2	38
9	A Mechanistic Pharmacokinetic/Pharmacodynamic Model of Factor D Inhibition in Cynomolgus Monkeys by Lampalizumab for the Treatment of Geographic Atrophy. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 288-296.	2.5	26
10	Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye. PLoS ONE, 2019, 14, e0218613.	2.5	20
11	Bivalent antibody pliers inhibit Î²-tryptase by an allosteric mechanism dependent on the IgG hinge. Nature Communications, 2020, 11, 6435.	12.8	18
12	Potent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate. MBio, 2021, 12, e0020221.	4.1	17
13	Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye. MAbs, 2017, 9, 1297-1305.	5.2	16
14	Hyaluronic Acidâ€“Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics. Bioconjugate Chemistry, 2019, 30, 2782-2789.	3.6	12
15	Nanolipoprotein Particles as a Delivery Platform for Fab Based Therapeutics. Bioconjugate Chemistry, 2020, 31, 1995-2007.	3.6	11
16	In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Molecular Pharmaceutics, 2019, 16, 86-95.	4.6	6
17	Dramatic activation of an antibody by a single amino acid change in framework. Scientific Reports, 2021, 11, 22365.	3.3	3
18	Fab-Nanolipoprotein Conjugate Causes Vitreous Opacity and Cataracts Following a Single Intravitreal Administration in New Zealand White Rabbits. Toxicologic Pathology, 2021, 49, 647-655.	1.8	0